IQVIA
the largest commercialization partner for named-patient and patient-support programs, drawing on data from more than 5,000 supported launches and the LAAD dataset; on 13 May 2026 it expanded its AI-enabled biosimilar collaboration with Kexing Biopharm (688136.SH) spanning clinical,…
- Country
- United States
- Ticker
- NYSE: IQV
us
psp
ai
Coverage
| CN | EU | US | |
|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Named-patient programs & compassionate use | market-access-commercial | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.